Back to results
US 2022/0178930 A1Published application
Anti-galectin-9 antibodies and uses thereof
AssigneesNew York University, PureTech LYT, Inc.
InventorsShohei KOIDE, George MILLER, Akiko KOIDE, Linxiao CHEN, Aleksandra FILIPOVIC, Eric ELENKO, Joseph BOLEN
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for identifying a subject as having certain solid cancers such as breast cancer, colorectal colon cancer, or non-small cell lung cancer, or being at risk for the cancer based on the level of Galectin-9 in a biological sample (e.g., a blood sample) from a subject suspected of having the solid cancer.
Claims33
-60. (canceled)
A method for identifying a human cancer patient and treating the human cancer patient, the method comprising:
- (i) providing a biological sample of a subject suspected of having a cancer,
- (ii) measuring the level of galectin-9 in the biological sample,
- (iii) identifying the subject as having the cancer or being at risk for the cancer based on the level of galectin-9 in the biological sample, wherein an elevated level of galectin-9 in the biological sample of the subject relative to a predetermined reference level indicates that the subject has the cancer or is at risk for the cancer and wherein the cancer is breast cancer, colorectal colon cancer (CRC), pancreatic cancer, or non-small cell lung cancer (NSCLC), and
- (iv) administering to the subject an effective amount of an anti-Galectin-9 antibody, wherein the anti-Galectin-9 antibody comprises a light chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:
- 1, a light chain complementary determining region 2 (CDR2) set forth as SEQ ID NO:
- 2, and a light chain complementary determining region 3 (CDR3) set forth as SEQ ID NO:
- 3 and comprises a heavy chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:
- 4, a heavy chain complementary determining region 2 (CDR2) set forth as SEQ ID NO:
- 5, and a heavy chain complementary determining region 3 (CDR3) set forth as SEQ ID NO:
- 6.
7 more elements
A method of treating a human subject having a solid tumor comprising:
- (i) providing a biological sample of a subject having a cancer,
- (ii) measuring the level of galectin-9 in the biological sample,
- (iii) identifying the subject as having the cancer based on the level of galectin-9 in the biological sample, wherein an elevated level of galectin-9 in the biological sample of the subject relative to a predetermined reference level indicates that the subject has the cancer, and wherein the cancer is breast cancer, colorectal colon cancer (CRC), pancreatic cancer, or non-small cell lung cancer (NSCLC), and
- (iv) administering to the subject a therapeutically effective amount an anti-Galectin-9 antibody, wherein the anti-Galectin-9 antibody comprises a light chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:
- 1, a light chain complementary determining region 2 (CDR2) set forth as SEQ ID NO:
- 2, and a light chain complementary determining region 3 (CDR3) set forth as SEQ ID NO:
- 3 and comprises a heavy chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:
- 4, a heavy chain complementary determining region 2 (CDR2) set forth as SEQ ID NO:
- 5, and a heavy chain complementary determining region 3 (CDR3) set forth as SEQ ID NO:
- 6.
7 more elements
Dependencies are inferred from the claim text.